Squarepoint Ops LLC Has $8.96 Million Stock Position in Kiniksa Pharmaceuticals International, plc $KNSA

Squarepoint Ops LLC reduced its stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 11.4% during the 2nd quarter, Holdings Channel reports. The fund owned 140,059 shares of the company’s stock after selling 18,034 shares during the period. Squarepoint Ops LLC’s holdings in Kiniksa Pharmaceuticals International were worth $8,957,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently made changes to their positions in the company. UBS Group AG increased its stake in shares of Kiniksa Pharmaceuticals International by 56.4% during the fourth quarter. UBS Group AG now owns 77,916 shares of the company’s stock worth $3,214,000 after purchasing an additional 28,099 shares during the period. Inspire Investing LLC acquired a new stake in Kiniksa Pharmaceuticals International during the 1st quarter worth approximately $1,698,000. BNP Paribas Financial Markets boosted its stake in Kiniksa Pharmaceuticals International by 27.3% in the 4th quarter. BNP Paribas Financial Markets now owns 831,777 shares of the company’s stock valued at $34,311,000 after purchasing an additional 178,366 shares during the period. SG Americas Securities LLC boosted its stake in Kiniksa Pharmaceuticals International by 18.2% in the 1st quarter. SG Americas Securities LLC now owns 640,179 shares of the company’s stock valued at $30,825,000 after purchasing an additional 98,783 shares during the period. Finally, OMERS ADMINISTRATION Corp acquired a new position in Kiniksa Pharmaceuticals International in the 1st quarter valued at $631,000. Institutional investors own 53.95% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on KNSA. Weiss Ratings cut Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, August 13th. Zacks Research cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 30th. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 12th. Canaccord Genuity Group raised their price target on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Finally, Citigroup lifted their price objective on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Eight analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, Kiniksa Pharmaceuticals International currently has a consensus rating of “Moderate Buy” and a consensus price target of $87.38.

Kiniksa Pharmaceuticals International Price Performance

Kiniksa Pharmaceuticals International stock opened at $76.48 on Friday. The firm has a market cap of $5.97 billion, a PE ratio of 78.85 and a beta of 0.09. The stock’s fifty day moving average price is $73.10 and its two-hundred day moving average price is $58.32. Kiniksa Pharmaceuticals International, plc has a one year low of $35.20 and a one year high of $82.94.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.30. Kiniksa Pharmaceuticals International had a return on equity of 13.65% and a net margin of 9.59%.The company had revenue of $243.60 million for the quarter, compared to analyst estimates of $226.49 million. Sell-side analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.37 earnings per share for the current fiscal year.

Insider Activity

In related news, CAO Michael Megna sold 4,600 shares of the company’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $80.30, for a total transaction of $369,380.00. Following the completion of the sale, the chief accounting officer owned 29,062 shares of the company’s stock, valued at $2,333,678.60. This represents a 13.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director G. Bradley Cole sold 3,673 shares of the stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total transaction of $299,092.39. Following the sale, the director owned 11,672 shares in the company, valued at $950,450.96. The trade was a 23.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 51.98% of the company’s stock.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International plc (NASDAQ: KNSA) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for patients with debilitating diseases, particularly conditions involving the immune system and inflammation. The company concentrates on areas of significant unmet medical need and uses biologic medicines and other targeted approaches in its research and development programs.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor.